Manish R. Patel

Research interests

Publications

• Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00826

• Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2300696

• Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2303810

• The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

  Nature · 2023 · 10.1038/s41586-023-05812-3

• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00224-5

• Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

  Clinical Cancer Research · 2021 · 10.1158/1078-0432.ccr-21-0715

• First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

  EClinicalMedicine · 2021 · 10.1016/j.eclinm.2021.100797

• Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

  JAMA Oncology · 2019 · 10.1001/jamaoncol.2018.5428

• Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.10.013

• Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

  JAMA Oncology · 2019 · 10.1001/jamaoncol.2018.6258

• Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

  Nature Medicine · 2019 · 10.1038/s41591-019-0474-7

• Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

  Blood · 2018 · 10.1182/blood-2018-08-869008

• Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30082-2

• PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.10.007

• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

  Blood · 2017 · 10.1182/blood-2017-04-779405

• Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.71.6795

• First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

  Cancer Discovery · 2017 · 10.1158/2159-8290.cd-17-1119

• Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

  Blood · 2017 · 10.1182/blood-2017-05-786566

• A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors

  Clinical Cancer Research · 2017 · 10.1158/1078-0432.ccr-16-2796

• Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30900-2

• Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(15)00584-7

• Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.68.1106

• Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

  Journal of Thoracic Oncology · 2015 · 10.1097/01.jto.0000473485.38553.f0

• Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70128-2

• M6P/IGF2 receptor: a candidate breast tumor suppressor gene.

  PubMed · 1996

Current projects

No projects listed.